Edition:
United Kingdom

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

982.00GBp
19 Jan 2018
Change (% chg)

-13.00 (-1.31%)
Prev Close
995.00
Open
990.40
Day's High
1,005.00
Day's Low
981.80
Volume
652,305
Avg. Vol
1,037,535
52-wk High
2,346.00
52-wk Low
906.50

Select another date:

Tue, Dec 19 2017

Hikma wins right to market Roche drug copy in Middle East and North Africa

Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.

Hikma wins right to market Roche drug copy in Middle East and North Africa

Dec 19 Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.

BRIEF-Hikma Pharmaceuticals ‍Reaches Licensing Agreement With Celltrion

* ‍REACHES LICENSING AGREEMENT WITH CELLTRION FOR THIRD BIOSIMILAR PRODUCT IN MIDDLE EAST AND NORTH AFRICA​

BRIEF-Hikma Says Hikma Ventures Has Participated In Financing For Prognos​

* ‍VENTURE CAPITAL ARM, HIKMA VENTURES HAS PARTICIPATED IN A $20.5 MILLION SERIES C ROUND OF FINANCING FOR PROGNOS​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

BRIEF-Hikma Pharmaceuticals ‍invests in biosensor tech firm Biolinq​

* HIKMA PHARMACEUTICALS PLC - ‍INVESTED IN BIOLINQ IN COLLABORATION WITH M VENTURES WHICH LED $10 MILLION SERIES A ROUND OF FINANCING​ Source text for Eikon: Further company coverage:

BRIEF-Hikma Pharmaceuticals acquires six products from Boehringer Ingelheim GmbH

* ‍HIKMA ACQUIRES PRODUCTS IN EUROPE FROM BOEHRINGER INGELHEIM​

Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

Hikma Pharmaceuticals Plc is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

UPDATE 1-Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

Nov 9 Hikma Pharmaceuticals Plc is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

Drugmaker Hikma cuts generics sales forecast a third time

Nov 9 Hikma Pharmaceuticals Plc on Thursday lowered 2017 revenue guidance for its generics business for a third time.

BRIEF-Hikma Pharmaceuticals says ‍continue to expect FY revenue around $2.0 bln​

* ‍CONTINUE TO EXPECT FULL YEAR REVENUE TO BE AROUND $2.0 BILLION IN CONSTANT CURRENCY IN 2017​

Select another date: